'Biosimilars market overview' presentation slideshows

Indonesia generated the highest revenue in the ASEAN biosimilars market in 2017 and is expected to remain dominant throughout the forecast period. Based on molecule type, the erythropoietin segment accounted for the second highest share in the ASEAN and China biosimilars market in 2017 and is expected to maintain this trend throughout the forecast period. Based on application, the blood disorders segment is estimated to rank second in terms of revenue in both, the ASEAN, and the China biosimilars market throughout the analysis period. The diabetes segment generated the highest CAGR from 2018 to 2025 in the ASEAN and China biosimilars market.

96 views • 8 slides